Antimicrobial prophylaxis in colorectal surgery: Focus on ertapenem

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 829-839

  De Lalla, Fausto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Colorectal surgery; Ertapenem; Surgical prophylaxis

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; ERTAPENEM; METRONIDAZOLE; NEOMYCIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL PAIN; ANTIBIOTIC PROPHYLAXIS; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM CONTAMINATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EXCRETION; DRUG HALF LIFE; DRUG SENSITIVITY; HUMAN; INFECTION PREVENTION; INTESTINE FLORA; MORTALITY; NAUSEA; PATHOPHYSIOLOGY; PHARMACODYNAMICS; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SURGICAL INFECTION; VOMITING;

EID: 77949429999     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3101     Document Type: Review

References (99)

1. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20:250-278.
2. Dimick JB, Chen SI, Taheri PA, Henderson WG, Khuri SF, Campbell DA Jr. Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program. J Am Coll Surg. 2004;199:531-537.
3. Khan NA, Quan H, Bugar JM, Lemaire JB, Brant R, Ghali WA. Association of postoperative complications with hospital costs and length of stay in a tertiary care center. J Gen Intern Med. 2006;21: 177-180.
4. Dimick JB, Pronovost PJ, Cowan JA, Lipsett PA. Complications and costs after high-risk surgery: where should we focus quality improvement initiatives? J Am Coll Surg. 2003;196:671-678.
5. Zhan C, Miller MR. Excess length of stay, charges and mortality attributable to medical injures during hospitalization. JAMA. 2003;290: 1868-1874.
6. Fleischman KE, Goldman I, Young B, Lee TH. Association between cardiac and noncardiac complications in patients undergoing non-cardiac surgery: outcomes and effects on length of stay. Am J Med. 2003;115:515-520.
7. Di Piro JT, Martindale RG, Bakst A, Vacani PF, Watson P, Miller MT. Infection in surgical patients: effects on mortality, hospitalization and postdischarge care. Am J Health Syst Pharm. 1998;55:777-781.
8. Kirkland KB, Briggs JP, Trivette SI, Wilkinson WE, Sexton DJ. The impact of surgical site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol. 1999;20:725-730.
9. Haley RW, Scabergh DR, Crossley KB, Von Allmen SD, McGowan JE Jr. Extra charges and prolongation of stay attributable to nosocomial infections: a prospective interhospital comparison. Am J Med. 1981; 70:51-58.
10. Eagye KJ, Nicolau DP. Deep and organ/space infections in patients undergoing elective colorectal surgery: incidence and impact on hospital length of stay and costs. Am J Surg. 2009;198(3):359-367.
11. Smith RL, Bohl JK, McElearney ST, et al. Wound infection after colorectal resection. Ann Surg. 2004;239:599-607.
12. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606-608.
13. Horan TC, Culver DH, Gaynes RP, Jarvis WR, Edwards JR, Reld CR. Nosocomial infections in surgical patients in the United States, January 1986-June 1992. National Nosocomial Infections Surveillance (NNIS) System. Infect Control Hosp Epidemiol. 1993;14:73-80.
14. Vegas AA, Jodra VM, Garcia ML. Nosocomial infections in surgical wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization. Eur J Epidemiol. 1993;9:504-510.
15. Nichols RL. Preventing surgical site infections: a surgeon's perspective. Emerg Infect Dis. 2001;7:220-224.
16. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993;6:438-442.
17. Leaper DJ, van Goor H, Reilly J, et al. Surgical site infection - a European perspective of incidence and economic burden. Int Wound J. 2004;1:247-273.
18. Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H Jr, Fagerstrom RM. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med. 1981;305:795-799.
19. Berard F, Gandon J. Postoperative wound infections: the influence of ultraviolet irradiation of the operating room and various other factors. Ann Surg. 1964;160(Suppl 2):1-192.
20. Krizek TJ, Robson MC. Evolution of quantitative bacteriology in wound management. Am J Surg. 1975;130:579-584.
21. Garibaldi RA, Cushing D, Lerer T. Risk factors for postoperative infection. Am J Med. 1991;91:158S-163S.
22. Haley RW, Culver DH, Morgan WM, White JW, Emori TG, Hooton TM. Identifying patients at high risk of surgical wound infection. A simple multivariate index of patient susceptibility and wound contamination. Am J Epidemiol. 1985;121:206-215.
23. Allen DB, Maguire JJ, Mahdavian M, et al. Wound hypoxia and acidosis limit neutrophil bacterial killing mechanisms. Arch Surg. 1997;132:991-996.
24. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med. 1996;334:1209-1215.
25. Gottrup F, Firmin R, Rabkin J, Halliday BJ, Hunt TK. Directly measured tissue oxygen tension and arterial oxygen tension assess tissue perfusion. Crit Care Med. 1987;15:1030-1036.
26. Hopf HW, Hunt TK, West JM, et al. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg. 1997;132:997-1004.
27. Kaye KS, Schmit K, Pieper C, et al. The effect of increasing age on the risk of surgical site infection. J Infect Dis. 2005;191:1056-1062.
28. Woodfield JC, Beshay NM, Pettigrew RA, Plank LD, van Rij AM. American Society of Anesthesiologists classification of physical status as a predictor of wound infection. Anz J Surg. 2007;77:738-741.
29. Choban PS, Heckler R, Burge JC, Flanebaum L. Increased incidence of nosocomial infection in obese surgical patients. Am Surg. 1995; 61:1001-1005.
30. Sutter VI. Frequency of occurrence and antimicrobial susceptibility of bacterial isolates from intestinal and female genital tracts. Rev Infect Dis. 1983;5(Suppl 1):S84-S89.
31. Barie PS. Emerging problems in Gram-positive infections in the post-operative patients. Surg Gynecol Obstet. 1993;177(Suppl):S55-S64.
32. Rovera F, Diurni M, Dionigi G, et al. Antibiotic prophylaxis in colorectal surgery. Expert Rev Anti Infect Ther. 2005;3:787-795.
33. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2006;36:592-598.
34. Gomez-Alonzo A, Lozano F, Perez A, Almazan A, Abdel-Lah A, Cuadrado F. Systematic prophylaxis with gentamicin-metronidazole in appendicectomy and colorectal surgery: a prospective controlled clinical study. Int Surg. 1984;69:17-20.
35. Gottrup F, Diederich P, Sorensen K, Nielson SV, Ornsholt J, Brandsborg O. Prophylaxis with whole gut irrigation and antimicrobials in colorectal surgery: a prospective, randomised double-blind clinical trial. Am J Surg. 1985;149:317-322.
36. Schiessel R, Huk I, Wunderlich M, Rotter M, Werwalka G, Schemper M. Postoperative infections in colonic surgery after enteral bacitracin-neomycin- clindamycin or parenteral mezlocillin-oxacillin prophylaxis. J Hosp Infect. 1984;5:289-297.
37. Utley RJ, Macbeth WA. Peroperative cefoxitin: a double-blind prospective study in the prevention of wound infection. J R Coll Surg Edinb. 1984;29:143-146.
38. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991;35:208-210.
39. Solla JA, Rothenberger D. Preoperative bowel preparation. A survey of colon and rectal surgeons. Dis Colon Rectum. 1990;33:154-159.
40. Nichols RL, Smith JW, Garcia R, Waterman RS, Holmes JW. Current practices of preoperative bowel preparation among North American colorectal surgeons. Clin Infect Dis. 1997;24:609-619.
41. Zmora O, Wexsner SD, Hajjar L, et al. Trends in preparation for colorectal surgery: survey of the members of the American Society of colon and rectal surgery. Am J Surg. 2003;69:154-160.
42. Nelson RL, Glenny AM, Song F. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev. 2009;1:CD001181.
43. Song F, Glenny AM. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials. Health Technol Assess. 1998;2(7):1-110.
44. Lewis RT. Oral versus systemic antibiotic prophylaxis in elective colon surgery: a randomized study and meta-analysis send a message from the 1990s. Can J Surg. 2002;45:173-180.
45. Espin-Basany E, Sanchez-Garcia JL, Lopez-Cano M, et al. Prospective, randomised study on antibiotic prophylaxis in colorectal surgery. It is really necessary to use oral antibiotics? Int J Colorectal Dis. 2005;20:542-546.
46. Kobayashi M, Mohri Y, Tonouchi H, et al. Randomized clinical trial comparing intravenous antimicrobial prophylaxis alone with oral and intravenous antimicrobial prophylaxis for the prevention of a surgical site infection in colorectal cancer surgery. Surg Today. 2007;37:383-388.
47. Peruzzo L, Savio S, de Lalla F. Systematic versus systematic plus oral chemoprophylaxis in elective colorectal surgery. Chemioterapia. 1987;6:601-602.
48. Yabata E, Okabe S, Endo M. A prospective, randomized clinical trial of preoperative bowel preparation for elective colorectal surgery - comparison among oral, systemic, and intraoperative luminal antibacterial preparations. J Med Dent Sci. 2007;44:75-80.
49. Wren SM, Ahmed N, Jamal A, Safadi BY. Preoperative oral antibiotics in colorectal surgery increase the rate of Clostridium difficile colitis. Arch Surg. 2005;140:752-756.
50. Wille-Jørgensen P, Guenaga KF, Matos D, Castro AA. Pre-operative mechanical bowel cleansing or not? An up-date meta-analysis. Colorectal Dis. 2005;7:304-310.
51. Nelson R, Singer M. Primary repair for penetrating colon injuries. Cochrane Database Syst Rev. 2003;3:CD002247.
52. Bucher P, Mermillod B, Gervaz P, Morel P. Mechanical bowel preparation for elective colorectal surgery: a meta-analysis. Arch Surg. 2004;139:1359-1364.
53. Guenaga KK, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev. 2009;1:CD001544.
54. Slim K, Vicaut E, Launay-Savary MV, Contant C, Chipponi J. Updated systematic review and meta-analysis of randomized clinical trials on the role of mechanical bowel preparation before colorectal surgery. Ann Surg. 2009;249:203-209.
55. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1707-1715.
56. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg. 2005;140:174-182.
57. Page CP, Bohnen JM, Fletcher JR, McManus AT, Solomkin JS, Wittmann DH. Antimicrobial prophylaxis for surgical wounds: guidelines for clinical care. Arch Surg. 1993;128:79-88.
58. Dellinger EP, Gross PA, Barrett TH, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. The Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 1994;15:182-188.
59. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 1999;56:1839-1888.
60. Gilbert DN, Moellering RC, Sande MA. The Sanford guide to antimicrobial therapy. 33rd ed. Hyde Park, VT: Antimicrobial Therapy; 2003. p. 123-124.
61. Livermore DM, Carter MW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother. 2001;45:1860-1867.
62. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother. 2001;45:1915-1918.
63. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother. 2000;44:2747-2751.
64. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother. 2003;52:331-344.
65. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother. 2002;46:3506-3511.
66. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem :an overview for clinicians. J Antimicrob Chemother. 2004;53(Suppl S2):S23-S28.
67. Wittau M, Wagner E, Kaever V, Koal T, Henne-Bruns D, Isenmann R. Intraabdominal tissue concentration of ertapenem. J Antimicrob Chemother. 2006;57:312-316.
68. Yellin AE, Hassett JM, Fernandez A, et al; 004 Intra-abdominal Infection Study Group. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adult. Int J Antimicrob Agents. 2002;20: 165-173.
69. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: result of a double-blind, randomized, comparative phase III trial. Ann Surg. 2003;237:235-245.
70. Roy S, Higared I, Angel-Muller E, et al. Ertapenem once day versus piperacillin/tazobactam every 6 h for treatment of acute pelvic infections: a prospective, multicenter, randomized, double blind study. Infect Dis Obstetr Gynaecol. 2003;11:27-37.
71. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A; Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002;34:1076-1083.
72. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34: 1460-1468.
73. Tomera KM, Burdmann EA, Reyna OG, et al; Protocol 014 Study Group. Ertapenem versus ceftriaxone followed by appropriate oral therapy for therapy of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2003;46:2895-2800.
74. Jimenez-Cruz F, Jasovich A, Cajigas J, et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002;60:16-22.
75. Itani KMF, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006;355:2640-2651.
76. Goldstein EJ, Citron DM, Merriam CV, Abramson MA. Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs ertapenem prophylaxis. Surg Infect. 2009;10:111-118.
77. Wilson SE, Turpin RS, Kumar RN, et al. Comparative costs of ertapenem and cefotetan as prophylaxis for elective colorectal surgery. Surg Infect. 2008;8:349-356.
78. Hershman MJ, Swift RI, Reilly DT, et al. Prospective, comparative study of cefotetan with piperacillin for prophylaxis against infection in elective colorectal surgery. J R Coll Surg Edinb. 1990;35:29-32.
79. Milsom JW, Smith DL, Corman ML, Howerton RA, Yellin AE, Luke DR. Double-blind comparison of single dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Am J Surg. 1998;176(Suppl 6 A):46S-52S.
80. Arnaud JP, Bellissant E, Boissel P, et al. Single-dose amoxycillin-clavulanic acid vs cefotetan for prophylaxis in elective colorectal surgery: a multicentre, prospective, randomized study. J Hosp Infect. 1992;22(Suppl A):S23-S32.
81. Bellantone R, Pacelli F, Sofo L, et al. Systemic perioperative prophylaxis in elective oncological colorectal surgery: cefotetan versus clindamicin plus aztreonam. Drugs Exp Clin Res. 1988;14:763-766.
82. Periti P, Mazzei T, Tonelli F. Single-dose cefotetan vs. multiple doses cefoxitin antimicrobial prophylaxis in colorectal surgery: results of a prospective, multicenter, randomized study. Dis Colon Rectum. 1989;32:121-127.
83. Periti P, Tonelli F, Mazzei T, Ficari F. Antimicrobial chemoimmunoprophylaxis in colorectal surgery with cefotetan and thymostimulin: prospective, controlled multicenter study. J Chemother. 1993;5: 37-42.
84. Skipper D, Karran SJ. A randomized prospective study to compare cefotetan with cefuroxime plus metronidazole as prophylaxis in elective colorectal surgery. J Hosp Infect. 1992;21:73-77.
85. Morton AL, Taylor EW, Lindsay G, Wells GR. A multicenter study to compare cefotetan alone with cefotetan and metronidazole as prophylaxis against infection in elective colorectal operations. Surg Gynecol Obstet. 1989;169:41-45.
86. Jagelman DG, Fabian TC, Nichols RL, Stone HH, Wilson SE, Zellner SR. Single-dose cefotetan versus multiple-dose cefoxitin as prophylaxis in colorectal surgery. Am J Surg. 1988;155:71-76.
87. Itani KM, Jensen EH, Finn TS, Tomassini JE, Abramson MA. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect. 2008;9:131-137.
88. Martin C, Portet C, Lambert D, et al. Pharmacokinetics and tissue penetration of single-dose cefotetan used for antimicrobial prophylaxis in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1992;36:1115-1118.
89. Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis. 2006;43: 322-330.
90. Song F, Glenny AM, Altman DG. Indirect comparison in evaluating efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials. 2000;21:488-497.
91. Sexton DJ. Carbapenem for surgical prophylaxis? N Engl J Med. 2006;366:2693-2695.
92. Dinubile MJ, Friedland D, Chan CY, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis. 2005;24:443-449.
93. Bartlett JG, Chang TW, Gurwith M, Gorbach SI, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531-534.
94. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut. 2008;57:850-860.
95. Weir E, Flegel K. Protecting against Clostridium difficile illness. CMAJ. 2005;172:1178.
96. Kuijper EJ, Coignard B, Tull P, et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):S2-S18.
97. Hubert B, Loo VG, Burgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis. 2007;44:238-244.
98. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.
99. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect. 2004;42:1203-1206.